XML 51 R36.htm IDEA: XBRL DOCUMENT v3.3.1.900
Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Feb. 27, 2015
shares
Oct. 16, 2009
Dec. 31, 2015
USD ($)
Tranche
Segment
shares
Dec. 31, 2014
USD ($)
shares
Dec. 31, 2013
USD ($)
Nov. 30, 2015
USD ($)
Mar. 05, 2015
USD ($)
May. 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Dec. 06, 2012
USD ($)
Significant Accounting Policies [Line Items]                    
Deferred revenue, current     $ 923,000   $ 1,700,000          
Sales discount percentage     2.00%              
Sales discount term     30 days              
Trade receivables, credit period     30 days              
Number of tranches for private placement transaction | Tranche     2              
Accounts receivable written off     $ 0              
Warrants outstanding | shares     0              
Gain (Loss) on change in fair value of derivative liability     $ (1,106,000) $ 13,472,000 $ 47,710,000          
Number of operating segments | Segment     1              
Biopharma Debt                    
Significant Accounting Policies [Line Items]                    
Gain (Loss) on change in fair value of derivative liability     $ (700,000) 6,300,000            
Maximum repayment of future revenue and receivables     137,300,000             $ 150,000,000
Fair value of embedded derivative liability                   $ 14,600,000
Embedded Derivative Financial Instruments                    
Significant Accounting Policies [Line Items]                    
Gain (Loss) on change in fair value of derivative liability     (270,000) 7,200,000            
Embedded Derivative Financial Instruments | Biopharma Debt                    
Significant Accounting Policies [Line Items]                    
Gain (Loss) on change in fair value of derivative liability     (700,000) 6,300,000            
Maximum repayment of future revenue and receivables                 $ 150,000,000  
Fair value of embedded derivative liability     5,500,000 $ 4,800,000            
Preferred Stock Purchase Option                    
Significant Accounting Policies [Line Items]                    
Gain (Loss) on change in fair value of derivative liability     $ (946,000)              
Derivative liability at fair value             $ 900,000      
Top Three Customers | Gross Product Sales | Customer Concentration Risk                    
Significant Accounting Policies [Line Items]                    
Concentration risk percentage     95.00% 95.00%            
Top Three Customers | Accounts Receivable | Customer Concentration Risk                    
Significant Accounting Policies [Line Items]                    
Concentration risk percentage     95.00% 96.00%            
Convertible Debt | 2014 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount               $ 27,900,000    
Derivative liability fair value assumptions, risk-free rate       2.70%            
Derivative liability fair value assumptions, dividend yield       24.80%            
Derivative liability fair value assumptions, volatility rate       82.00%            
Gain (Loss) on change in fair value of derivative liability     $ 500,000 $ 900,000            
Fair value of embedded derivative liability     2,100,000 $ 2,600,000            
Derivative liability at fair value               $ 3,500,000    
Convertible Debt | 2015 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount           $ 3,800,000        
Gain (Loss) on change in fair value of derivative liability     (100,000)              
Fair value of embedded derivative liability     $ 600,000              
Derivative liability at fair value           $ 500,000        
Convertible Debt | 2014 Notes and 2015 Notes                    
Significant Accounting Policies [Line Items]                    
Derivative liability fair value assumptions, risk-free rate     2.90% 2.70%            
Derivative liability fair value assumptions, dividend yield     25.60% 24.80%            
Derivative liability fair value assumptions, volatility rate     89.00% 82.00%            
Convertible Debt | 2012 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount     $ 0 $ 0            
Convertible Debt | Non Cash | 2014 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount     22,400,000 $ 28,200,000            
Convertible Debt | Non Cash | 2015 Notes                    
Significant Accounting Policies [Line Items]                    
Convertible senior notes, discount     $ 4,100,000              
Warrants Issued October 2009                    
Significant Accounting Policies [Line Items]                    
Warrants expiration date     Feb. 27, 2015              
Warrants outstanding | shares     0 8,087,388            
Warrants exercised | shares     1,844,585              
Warrants expired | shares 6,242,803                  
Warrant derivative liability       $ 100,000            
Derivative liability fair value assumptions, risk-free rate       0.04%            
Derivative liability fair value assumptions, term       1 month 28 days            
Derivative liability fair value assumptions, dividend yield       0.00%            
Derivative liability fair value assumptions, volatility rate       79.00%            
Gain (Loss) on change in fair value of derivative liability     $ 110,000              
Decrease in fair value of warrants     $ 100,000              
Warrants Issued October 2009 | Prior To Agreement                    
Significant Accounting Policies [Line Items]                    
Warrants expiration date   Oct. 16, 2014                
Maximum | Embedded Derivative Financial Instruments | Biopharma Debt                    
Significant Accounting Policies [Line Items]                    
Derivative liability fair value assumptions, term     7 years 3 months 18 days 3 years 7 months 6 days            
Derivative liability fair value assumption, coupon rate     12.50% 10.80%            
Derivative liability fair value assumptions, market yields     30.70% 16.80%            
Minimum | Embedded Derivative Financial Instruments | Biopharma Debt                    
Significant Accounting Policies [Line Items]                    
Derivative liability fair value assumptions, term     2 years 2 years 3 months 18 days            
Derivative liability fair value assumption, coupon rate     6.60% 9.80%            
Derivative liability fair value assumptions, market yields     13.00% 10.00%